Just a little over a year after it emerged from stealth mode, the company - which recently initiated a clinical trial of a drug targeting allosteric mutations in solid tumors - has filed to go public.
The company, led by a Gilead Sciences veteran, plans to use the platform to find drugs that go after "undruggable" targets.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
The company has a 10,000-patient prospective trial with Geisinger fully enrolled to test CancerSEEK, a test developed at Johns Hopkins University.
The Houston-based company is developing a cell therapy for viral infections in patients with compromised immune systems, which it plans to move into Phase III studies within the next 12 months. AlloVir also raised $120 million in a Series B funding round.
The company hopes to start IND-enabling studies and clinical trials next year of orally available drugs in a class currently dominated by injected monoclonal antibodies.
The company will use funding to bring cell therapies into clinic in oncology and autoimmune indications.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.